Corixa Corporation

Ribi Immunochem Research, Inc.

Patricia A Weber

C Gregory Sowell

David A Johnson

Greg Sowell

Methods for treating diseases or conditions modulated or ameliorated by nitric oxide, particularly ischemia and reperfusion injury, are provided, using glycolipids structurally related to monophosphoryl lipid A but with notable reduction in proinflammatory and pyrogenic activity.

Mono- and disaccharides for the treatment of nitric oxide related disorders

The invention concerns a novel phosphoglycolipid compound. The compound of the subject invention is 2-Deoxy-6-O-&lsqb;2-deoxy-4-O-phosphono-3-O-&lsqb;(R)-3-tetradecanoyloxytetradecanoyl&rsqb;-2-&lsqb;(R)-3-octadecanoyloxytetradecanoylamino&rsqb;-&bgr;- -glucopyranosyl&rsqb;-2-&lsqb;(R)-3-hexadecanoyloxytetradecanoylamino&rsqb;- -glucopyranose and pharmaceutically acceptable salts thereof. The compound is not immunoreactive, not pyrogenic, not toxic but is active in ameliorating tissue damage due to ischemia/reperfusion injury. Methods for using the subject compound to protect against reversible and irreversible damage due to ischemia/reperfusion injury are also disclosed.

Phosphoglycolipid and methods for its use

The invention concerns a novel phosphoglycolipid compound. The compound of the subject invention is 2-Deoxy-6-O-[2-deoxy-4-O-phosphono-3-O-[(R)-3-tetradecanoyloxytetradecanoy l]-2-[(R)-3-octadecanoyloxytetradecanoylamino]-.beta.-D-glucopyranosyl]-2-[ (R)-3-hexadecanoyloxytetradecanoylamino]-D-glucopyranose and pharmaceutically acceptable salts thereof. The compound is not immunoreactive, not pyrogenic, not toxic but is active in ameliorating tissue damage due to ischemia/reperfusion injury. Methods for using the subject compound to protect against reversible and irreversible damage due to ischemia/reperfusion injury are also disclosed.

Growing community of inventors

Hamilton, MT, United States of America

Patricia A Weber